Advertisement
ANIK vs INFU
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a Buy and INFU is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIK’s FA Score shows that 0 FA rating(s) are green whileINFU’s FA Score has 0 green FA rating(s).
- ANIK’s FA Score: 0 green, 5 red.
- INFU’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIK’s TA Score shows that 3 TA indicator(s) are bullish while INFU’s TA Score has 4 bullish TA indicator(s).
- ANIK’s TA Score: 3 bullish, 3 bearish.
- INFU’s TA Score: 4 bullish, 5 bearish.
Price Growth
ANIK (@Pharmaceuticals: Generic) experienced а +1.24% price change this week, while INFU (@Pharmaceuticals: Other) price change was +3.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.97%. For the same industry, the average monthly price growth was +24.39%, and the average quarterly price growth was +67.10%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.27%, and the average quarterly price growth was +8.57%.
Reported Earning Dates
ANIK is expected to report earnings on Oct 30, 2025.
INFU is expected to report earnings on Nov 11, 2025.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.97% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Pharmaceuticals: Other (-1.23% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ANIK | INFU | ANIK / INFU | |
| Capitalization | 130M | 206M | 63% |
| EBITDA | -2.24M | 23.5M | -10% |
| Gain YTD | -45.322 | 19.290 | -235% |
| P/E Ratio | N/A | 42.00 | - |
| Revenue | 115M | 140M | 82% |
| Total Cash | 53.2M | 720K | 7,389% |
| Total Debt | 25M | 30.5M | 82% |
ANIK | INFU | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 73 | |
PRICE GROWTH RATING 1..100 | 89 | 38 | |
P/E GROWTH RATING 1..100 | 69 | 100 | |
SEASONALITY SCORE 1..100 | 25 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INFU's Valuation (72) in the Medical Specialties industry is in the same range as ANIK (92) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
INFU's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
INFU's SMR Rating (73) in the Medical Specialties industry is in the same range as ANIK (97) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
INFU's Price Growth Rating (38) in the Medical Specialties industry is somewhat better than the same rating for ANIK (89) in the Pharmaceuticals Other industry. This means that INFU’s stock grew somewhat faster than ANIK’s over the last 12 months.
ANIK's P/E Growth Rating (69) in the Pharmaceuticals Other industry is in the same range as INFU (100) in the Medical Specialties industry. This means that ANIK’s stock grew similarly to INFU’s over the last 12 months.
| ANIK | INFU | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 75% |
| Advances ODDS (%) | 9 days ago 64% | 18 days ago 70% |
| Declines ODDS (%) | 2 days ago 69% | 10 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 79% |
| Aroon ODDS (%) | N/A | 2 days ago 72% |
Advertisement
ANIK and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with AVNS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then AVNS could also see price increases.
| Ticker / NAME | Correlation To ANIK | 1D Price Change % | ||
|---|---|---|---|---|
| ANIK | 100% | -0.77% | ||
| AVNS - ANIK | 37% Loosely correlated | -4.55% | ||
| FLGT - ANIK | 34% Loosely correlated | -0.32% | ||
| ORGO - ANIK | 33% Poorly correlated | -4.49% | ||
| LIVN - ANIK | 32% Poorly correlated | -1.78% | ||
| INFU - ANIK | 30% Poorly correlated | -1.66% | ||
More | ||||
INFU and
Correlation & Price change
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with QDEL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then QDEL could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | -1.66% | ||
| QDEL - INFU | 38% Loosely correlated | -0.58% | ||
| TMCI - INFU | 37% Loosely correlated | -1.47% | ||
| RDNT - INFU | 36% Loosely correlated | -0.56% | ||
| IRMD - INFU | 35% Loosely correlated | -2.39% | ||
| CERS - INFU | 34% Loosely correlated | -1.95% | ||
More | ||||